logo-loader
viewBioCorRx Inc.

BioCorRx advances development of opioid abuse treatment BICX102 amid coronavirus pandemic

CEO Brady Granier said the company’s pivotal GLP preclinical studies of BICX102 “continue to progress and have been uninterrupted"

BioCorRx Inc. - BioCorRx Inc’s development of its naltrexone implant BICX102 to treat opioid and alcohol use disorder not affected by coronavirus pandemic
BioCorRx expects to submit an Investigational New Drug application to the US FDA near the year-end

BioCorRx Inc (OTCQB:BICX) said Friday that the development of its naltrexone implant BICX102 to treat opioid and alcohol use disorder has not been affected by the coronavirus (COVD-19) pandemic.

In a statement, CEO Brady Granier said the company’s pivotal GLP preclinical studies of BICX102 “continue to progress and have been uninterrupted by COVID-19 to date.”

Granier also noted that the studies started before the United States began shutting down in late March and added that BioCorRx expects to have the data and reports needed to submit an Investigational New Drug (IND) application to the US Food and Drug Administration near the year end.

READ: BioCorRx announces two senior management promotions as company eyes next growth phase

The drug naltrexone, delivered in the sustained-release implant, is designed to decrease the desire to take opioids. 

In addition, Granier said the company continues to advance preclinical studies with VDM-001, a new molecule being developed to reverse opioid overdose through a partnership with VDM Biochemicals Inc. 

“VDM-001 may represent an effective alternative to naloxone in the overdose reversal market,” he said.

“Early preclinical data was promising as the effects of fentanyl, which is responsible for thousands of deaths annually, may be prevented by VDM-001. We are currently conducting more preclinical studies to gain more knowledge about the viability of this novel molecule.”

In other company news, the group said it is, for a limited time, offering free access to its BioCorRx Recovery Program mobile platform for medical professionals and the UnCraveRx app for anyone who wants to track their fitness and nutritional goals. 

The mobile app also provides patients and treatment providers a means of engaging during stay-at-home orders, according to the Anaheim, California-based company.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: BioCorRx Inc.

Price: 2.398 USD

OTCMKTS:BICX
Market: OTCQB
Market Cap: $12.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioCorRx Inc. named herein, including the promotion by the Company of BioCorRx Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BioCorRx offers medical professionals free use of its...

BioCorRx Inc (OTCQB:BICX) CEO Brady Granier tells Proactive the California-based company will help support vulnerable patients recover from alcohol or drug dependencies through the coronavirus pandemic. Granier says the addiction treatment solutions company is offering free access to its...

on 04/07/2020

2 min read